Goflikicept Uses, Dosage, Side Effects and more
Goflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-cov-2) Infection (COVID-19)).
Attribute | Details |
---|---|
Trade Name | Goflikicept |
Generic | Goflikicept |
Goflikicept Other Names | Goflikicept |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |
How Goflikicept works
Goflikicept is a fusion protein that neutralizes interleukin-1B (IL-1B), affecting its signalling pathways. As IL-1B is involved in 'cytokine storm' efects, goflikicept's effects on the molecule inhibits widespread inflammation.